---
title: 'Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative
  disorder: The phase 2 TIDaL trial'
date: '2024-04-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38643491/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240422180751&v=2.18.0.post9+e462414
source: Blood
description: Post-transplant lymphoproliferative disorder (PTLD) is a rare complication
  of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related
  morbidity and mortality. Current treatment takes a sequential, risk-stratified approach,
  patients with low-risk disease following initial immunotherapy can avoid escalation
  to immunochemotherapy. TIDaL is a prospective, single-arm phase 2 trial investigating
  the activity and tolerability of ibrutinib combined ...
disable_comments: true
---
Post-transplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified approach, patients with low-risk disease following initial immunotherapy can avoid escalation to immunochemotherapy. TIDaL is a prospective, single-arm phase 2 trial investigating the activity and tolerability of ibrutinib combined ...